StreetInsider.com News Articles

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.

World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.

Defence to

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.
World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.
Defence to

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.
World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.
Defence to

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.
World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.
Defence to

Defence Therapeutics names ex-Xenon CFO Sherry Aulin to its board

Tue, 29 Sep 2026 03:16:11 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.

Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.

Earlier in her career, Aulin held senior roles at KPMG

Defence Therapeutics names ex-Xenon CFO Sherry Aulin to its board

Tue, 29 Sep 2026 03:16:11 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.

Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.

Earlier in her career, Aulin held senior roles at KPMG

Defence Therapeutics names ex-Xenon CFO Sherry Aulin to its board

Tue, 29 Sep 2026 03:16:11 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.

Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.

Earlier in her career, Aulin held senior roles at KPMG

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")

Defence Therapeutics CEO outlines three strategic priorities in letter

Tue, 08 Sep 2026 06:13:59 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) CEO Dr. Amie Phinney has published a letter to shareholders outlining the biotechnology company's strategic direction, according to a press release dated September 8, 2026.
Phinney, who recently assumed the role of president and CEO, identified three core development areas: Accum®-enhanced antibody-drug conjugates (ADCs), Accum®-enabled radiotherapeutics, and determining the path forward for the company's clinical-stage AccuTOX® program.
On the ADC front, the company stated it does not intend to compete with ADC developers but rather to partner with them. The commercial objective is to generate revenue through partnerships and licensing agreements, with proceeds intended to

Defence Therapeutics CEO outlines three strategic priorities in letter

Tue, 08 Sep 2026 06:13:59 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) CEO Dr. Amie Phinney has published a letter to shareholders outlining the biotechnology company's strategic direction, according to a press release dated September 8, 2026.
Phinney, who recently assumed the role of president and CEO, identified three core development areas: Accum®-enhanced antibody-drug conjugates (ADCs), Accum®-enabled radiotherapeutics, and determining the path forward for the company's clinical-stage AccuTOX® program.
On the ADC front, the company stated it does not intend to compete with ADC developers but rather to partner with them. The commercial objective is to generate revenue through partnerships and licensing agreements, with proceeds intended to

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.
Dear Shareholders,
Defence Therapeutics is entering an exciting new stage in its evolution, and I am honoured to have the opportunity to lead the company forward. My first month as CEO has been focused on deepening my understanding

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.
Dear Shareholders,
Defence Therapeutics is entering an exciting new stage in its evolution, and I am honoured to have the opportunity to lead the company forward. My first month as CEO has been focused on deepening my understanding

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.
Dear Shareholders,
Defence Therapeutics is entering an exciting new stage in its evolution, and I am honoured to have the opportunity to lead the company forward. My first month as CEO has been focused on deepening my understanding

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.
Dear Shareholders,
Defence Therapeutics is entering an exciting new stage in its evolution, and I am honoured to have the opportunity to lead the company forward. My first month as CEO has been focused on deepening my understanding

Defence Therapeutics Provides Updates on Sharing Agreement

Fri, 04 Sep 2026 18:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 2026.
On March 6, 2026, the Company completed a non-brokered private placement in which it issued 17,445,455 units of the Company ("Units") at a price of $0.55 per unit for gross proceeds of $9,595,000.25 (the "Offering"). Of the

Defence Therapeutics Provides Updates on Sharing Agreement

Fri, 04 Sep 2026 18:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 2026.
On March 6, 2026, the Company completed a non-brokered private placement in which it issued 17,445,455 units of the Company ("Units") at a price of $0.55 per unit for gross proceeds of $9,595,000.25 (the "Offering"). Of the